alpha-Methyltyrosine (Metirosine)

Subscribe to Selected New Research on alpha-Methyltyrosine

216 relevant articles (4 outcomes, 7 trials/studies) found for this Drug

Description: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)

Also Known As:

Metirosine; Demser; Metyrosine; DL-Tyrosine, alpha-methyl-; Merck Brand of Metyrosine; Merck Sharp & Dohme Brand of Metyrosine; Racemetirosine; alpha-MPT; alpha-Methyl-para-tyrosine; alpha-Methyltyrosine Hydrochloride; alpha-Methyltyrosine, (+,-)-Isomer; alpha-Methyltyrosine, (D,L)-Isomer; alpha-Methyltyrosine, (L)-Isomer; Hydrochloride, alpha-Methyltyrosine; Metyrosine Merck Brand; alpha MPT; alpha Methyl p tyrosine; alpha Methyl para tyrosine; alpha Methyltyrosine; alpha Methyltyrosine Hydrochloride; alpha-methyl- DL-Tyrosine; alpha-Methyl-p-tyrosine

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8536

Cyclic Amino Acids: 1

Aromatic Amino Acids: 226

Tyrosine: 5345

Methyltyrosines

alpha-Methyltyrosine: 216

Experts

1.	Endo, Keigo: 2 articles (11/2007 - 02/2007)
2.	Oriuchi, Noboru: 2 articles (11/2007 - 02/2007)
3.	Kanai, Yoshikatsu: 1 article (11/2007)
4.	Kaira, Kyoichi: 1 article (11/2007)
5.	Hisada, Takeshi: 1 article (11/2007)
6.	Dobashi, Kunio: 1 article (11/2007)
7.	Imai, Hisao: 1 article (11/2007)
8.	Ishizuka, Tamotsu: 1 article (11/2007)
9.	Otani, Yoshimi: 1 article (11/2007)
10.	Yanagitani, Noriko: 1 article (11/2007)

Related Diseases

1.	Pheochromocytoma 04/28/1997 - "Metyrosine and pheochromocytoma." 11/01/1990 - "Surgical management of pheochromocytoma with the use of metyrosine." 05/01/1990 - "A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine." 11/01/1988 - "For patients with inoperable, malignant, recurrent, or multicentric pheochromocytomas, chronic medical therapy is indicated in the form of alpha- and/or beta-blockade or inhibition of catecholamine synthesis with alpha-methyl-para-tyrosine" 11/01/1985 - "Other investigators have advocated alpha-methyltyrosine as the medical therapy of choice in the preoperative preparation of patients with pheochromocytoma" Order ALL the reference details at left...
2.	Anoxia (Hypoxia) 01/01/1998 - "Rasagiline at 0.5 mg/kg/day was protective against alpha-MpT also in hypoxia-lesioned rats" 04/01/1986 - "Similarly, treatment with alpha-methyl-p-tyrosine decreased the ability of chemoreceptors to respond to hypoxia and hypercapnia and, in a few instances, these receptors could only be excited by superfusion of nitrogen-equilibrated medium" 06/01/1978 - "5. The animals were exposed to alternate periods of hypoxia and hyperoxia following administration of the tyrosine hydroxylase inhibitor alpha-methyl p-tyrosine (AMPT, 0.2-10 mg/kg, I.A.)" 08/01/1996 - "Reserpine (which depletes dopamine stores) but not alpha-methyl-para-tyrosine (which decreases de novo synthesis of dopamine) caused a marked attenuation of this hyperpolarisation [IR decrease only from 163.32 +/- 44.42 M omega pre-hypoxia to 154.42 +/- 50.97 M omega during hypoxia]" 07/15/1996 - "Depleting the brain of catecholamines prior to hypoxia, by treating the animals with alpha-methyl-p-tyrosine (AMT), resulted in a major change in the hsp72 mRNA expression" Order ALL the reference details at left...
3.	Body Weight (Weight, Body) 06/01/1983 - "Ten hr prior to the microinjection, alpha-methyl-p-tyrosine (250 mg/kg body weight) was intraperitoneally injected to prevent spontaneous pulsatile GH release" 06/01/1983 - "Ethanol (1-1.5 g/kg body weight, i.p.) improved acquisition of active avoidance responding only in ALA, whereas alpha-methyl-p-tyrosine (AMPT; 80 mg/kg body weight, i.p.) seemed to selectively impair acquisition of responding in AHA" 01/10/2000 - "Dopamine depletion was achieved by per-oral administration of 5.5 g/70 kg body weight alpha-methyl-para-tyrosine given in 37 h" 05/01/1984 - "The effects of daily intraperitoneal (150 mg/kg of body weight) injections of alpha-methyl-dl-tyrosine (MT), an inhibitor of tyrosine hydroxylase, on the 2nd to 4th, 5th to 7th or 10th to 12th days of life on the pituitary-adrenal function and brain adrenaline level in 3 to 4-month old rats were studied" 06/01/1979 - "Morphine (1.67, 5, and 15 mg/kg of body weight, intraperitoneally) altered dopamine turnover as measured by the alpha-methyl-p-tyrosine method in the median eminence, neostriatum, and frontal cortex of male Sprague-Dawley rats" Order ALL the reference details at left...
4.	Seasonal Affective Disorder 11/01/2001 - "Effects of alpha-methyl-para-tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission." Order ALL the reference details at left...
5.	Glioma (Gliomas) 08/01/2001 - "The aim of this study was to evaluate the prognostic value of SPECT imaging using the amino acid analog 3-[(123)I]iodo-L-alpha-methyltyrosine (IMT) in patients with gliomas" 08/01/2001 - "Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas." 10/01/1999 - "Kinetics of 3-[(123)I]iodo-l-alpha-methyltyrosine transport in rat C6 glioma cells." 04/01/1997 - "This study compares the uptake of the nonmetabolizable amino acid analog 3-[123I]iodo-alpha-methyltyrosine (IMT) and of [methyl-11C]-L-methionine (MET) in cerebral gliomas" 02/01/1999 - "Based on the results of stereotactic biopsy, we evaluated in a prospective fashion the efficiency of l-3-[123I]iodo-alpha-methyltyrosine-single-photon emission tomography (SPET) and [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the detection and grading of recurrences in patients previously treated for gliomas" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Phenoxybenzamine
2.	Ethanol (Ethyl Alcohol)
3.	Somatostatin (Somatotropin Release-Inhibiting Factor)
4.	rasagiline (Azilect)
5.	Reserpine (Serpasil)
6.	Dopamine (Intropin)
7.	Levodopa (L Dopa)
8.	Tyrosine (L-Tyrosine)
9.	Tryptophan (L-Tryptophan)
10.	Methionine (L-Methionine)

Related Therapies and Procedures

1.	Preoperative Care
2.	Ligation
3.	Induced Hypothermia
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Pheochromocytoma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 115 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>